# Wegovy Goes Oral: Inside the New Pill, Liver Fat Breakthroughs, and the Race to Reshape Obesity Treatment
Wegovy is no longer just a weekly injection — it's now a daily pill, and the data is rolling in fast. In this episode, we break down the biggest Wegovy headlines reshaping the weight management conversation, from real-world results to surprising liver health findings and a heated battle for market dominance.
We dig into Novo Nordisk's OCTANE study, which found that adults switching from injectable semaglutide or tirzepatide (Zepbound) to the oral Wegovy pill lost an average of 4.1% of body weight in just three months. We explain what this real-world data actually shows — and why it's different from the controlled OASIS 4 trial, which reported up to 16.6% weight loss in adherent patients.
Then we turn to the liver: new STEP UP trial data presented in Milan reveals dramatic reductions in liver fat among people taking Wegovy, with many participants reaching normal liver fat levels after 72 weeks. We unpack what this could mean for metabolic health and MASH (metabolic dysfunction-associated steatohepatitis) treatment — and why the findings, while promising, aren't the full picture yet.
Finally, we explore the business side of the story: Novo Nordisk's rivalry with Eli Lilly's Zepbound, predictions that oral drugs could capture half the global obesity market by 2030, upcoming treatments like amycretin and CagriSema, and FDA pushback over Wegovy's "Live Lighter" ad campaign.
Whether you're a patient, provider, or just following the GLP-1 drug boom, this episode delivers a clear, evidence-based breakdown of where Wegovy stands today — and where it's headed next.
**Topics covered:** Wegovy pill vs. injection, semaglutide weight loss results, OCTANE and OASIS 4
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
